{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"podcast":4,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04210115\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT04210115","nct_id":"NCT04210115","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04210115. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either:\n\n* FP therapy: cisplatin 75 mg/m\\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)\\] 1000 mg/m\\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray \\[Gy\\] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR\n* FOLFOX therapy: oxaliplatin 85 mg/m\\^2 AND either leucovorin 400 mg/m\\^2 OR levoleucovorin 200 mg/m\\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m\\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m\\^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.\n\nAll treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year.","label":"Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy","type":"EXPERIMENTAL"},{"description":"Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either:\n\n* FP therapy: cisplatin 75 mg/m\\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m\\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR\n* FOLFOX therapy: oxaliplatin 85 mg/m\\^2 AND either leucovorin 400 mg/m\\^2 OR levoleucovorin 200 mg/m\\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m\\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m\\^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle.\n\nAll treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year.","label":"Placebo+FP or FOLFOX Therapy+Radiotherapy","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-06-23","type":"ACTUAL"},"conditions":["Esophageal Squamous Cell Carcinoma (ESCC)","Gastroesophageal Junction Carcinoma (GEJC)","Esophageal Adenocarcinoma (EAC)"],"enrollment":{"count":703,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"pembrolizumab","type":"BIOLOGICAL"},{"name":"placebo","type":"DRUG"},{"name":"cisplatin","type":"DRUG"},{"name":"5-FU","type":"DRUG"},{"name":"radiotherapy","type":"RADIATION"},{"name":"leucovorin","type":"DRUG"},{"name":"levoleucovorin","type":"DRUG"},{"name":"oxaliplatin","type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2026-01-21","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free Survival (EFS)","timeFrame":"Up to ~60 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to ~72 months"}],"references":[{"citation":"Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3.","pmid":"33533655","type":"DERIVED"}],"start_date":{"date":"2020-02-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","url":"https://clinicaltrials.gov/study/NCT04210115"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04210115"}